LLY•benzinga•
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Summary
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 2, 2025 by benzinga